Publications

EULAST trial:

 

Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).

Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthøj B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, Kemmler G, Schurr T; EULAST Study Group; Davidson M, Kahn RS, Fleischhacker WW.Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27.PMID: 36716759 

 

 

EUFEST trial:

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group.Lancet. 2008 Mar 29;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.PMID: 18374841 

 

Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST.

Fleischhacker WW, Derks E, Kahn RS.Schizophr Res. 2012 Jun;138(1):39-40. doi: 10.1016/j.schres.2012.03.027. Epub 2012 Apr 27.PMID: 22542244

 

Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.

Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J; EUFEST Study Group.Eur Neuropsychopharmacol. 2014 Sep;24(9):1500-5. doi: 10.1016/j.euroneuro.2014.07.001. Epub 2014 Jul 21.PMID: 25085534

 

Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.

Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker WW; EUFEST study group.Schizophr Res. 2013 Jun;147(1):132-139. doi: 10.1016/j.schres.2013.03.001. Epub 2013 Mar 26.PMID: 23537477 

 

Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J.Eur Neuropsychopharmacol. 2015 Aug;25(8):1158-66. doi: 10.1016/j.euroneuro.2015.04.003. Epub 2015 Apr 30.PMID: 26004980

 

Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).

Landolt K, Rössler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.Schizophr Res. 2016 Apr;172(1-3):145-51. doi: 10.1016/j.schres.2016.01.046. Epub 2016 Feb 26.PMID: 26922655 

 

Familial sinistrality and handedness in patients with first episode schizophrenia: the EUFEST study.

Dollfus S, Alary M, Razafimandimby A, Prelipceanu D, Rybakowski JK, Davidson M, Galderisi S, Libiger J, Hranov LG, Hummer M, Boter H, Peuskens J, Kahn RS, Fleischhacker WW; EUFEST Group.Laterality. 2012;17(2):217-24. doi: 10.1080/1357650X.2011.558510. Epub 2011 Sep 14.PMID: 22385143

 

Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST).

Pijnenborg GH, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A.Eur Neuropsychopharmacol. 2015 Jun;25(6):808-16. doi: 10.1016/j.euroneuro.2015.02.012. Epub 2015 Apr 20.PMID: 25907250 

 

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rössler W, Fleischhacker WW; EUFEST Study Group.Eur Neuropsychopharmacol. 2010 May;20(5):310-6. doi: 10.1016/j.euroneuro.2010.02.001. Epub 2010 Mar 3.PMID: 20202800 

 

Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Volavka J, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Czobor P.Eur Psychiatry. 2016 Jan;31:13-9. doi: 10.1016/j.eurpsy.2015.10.003. Epub 2015 Dec 4.PMID: 26657597 

 

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group.Schizophr Res. 2009 Dec;115(2-3):104-14. doi: 10.1016/j.schres.2009.09.022. Epub 2009 Oct 12.PMID: 19822407

 

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.J Clin Psychiatry. 2011 Jul;72(7):955-61. doi: 10.4088/JCP.10m06529.PMID: 21824456

 

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Fleischhacker WW, Keet IP, Kahn RS; EUFEST Steering Committee.Schizophr Res. 2005 Oct 15;78(2-3):147-56. doi: 10.1016/j.schres.2005.06.004.PMID: 16055308 

 

Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).

Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS; EUFEST Study Group.J Clin Psychiatry. 2010 Jan;71(1):58-65. doi: 10.4088/JCP.08m04506yel. Epub 2009 Oct 20.PMID: 19852905 

 

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS.Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15.PMID: 19369319 

 

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS; EUFEST study group.Schizophr Res. 2009 Dec;115(2-3):97-103. doi: 10.1016/j.schres.2009.09.019. Epub 2009 Oct 9.PMID: 19819114 

 

The interrelation of needs and quality of life in first-episode schizophrenia.

Landolt K, Rössler W, Burns T, Ajdacic-Gross V, Galderisi S, Libiger J, Naber D, Derks EM, Kahn RS, Fleischhacker WW.Eur Arch Psychiatry Clin Neurosci. 2012 Apr;262(3):207-16. doi: 10.1007/s00406-011-0275-6. Epub 2011 Nov 24.PMID: 22113521

 

Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis.

Riecher-Rössler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P, Fleischhacker WW; EUFEST Study Group.Psychol Med. 2013 Dec;43(12):2571-82. doi: 10.1017/S0033291713000226. Epub 2013 Apr 17.PMID: 23590895

 

Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective.

Landolt K, Rössler W, Burns T, Ajdacic-Gross V, Galderisi S, Libiger J, Naber D, Derks EM, Kahn RS, Fleischhacker WW; EUFEST Study Group.Psychol Med. 2012 Jul;42(7):1461-73. doi: 10.1017/S0033291711002406. Epub 2011 Nov 21.PMID: 22099529 

 

Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial.

Czobor P, Volavka J, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.J Clin Psychopharmacol. 2013 Apr;33(2):258-61. doi: 10.1097/JCP.0b013e3182856886.PMID: 23422388 

 

Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial.

Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW; EUFEST Study Group.J Clin Psychopharmacol. 2011 Jun;31(3):274-80. doi: 10.1097/JCP.0b013e3182199bcc.PMID: 21508850 

 

Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.

Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS; Eufest Study Group.Eur Neuropsychopharmacol. 2013 Mar;23(3):196-204. doi: 10.1016/j.euroneuro.2012.04.019. Epub 2012 May 28.PMID: 22647933 

 

Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach.

Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, Falkai P, Wobrock T, Derks EM, Fleischhacker WW, Hasan A.Lancet Psychiatry. 2016 Oct;3(10):935-946. doi: 10.1016/S2215-0366(16)30171-7. Epub 2016 Aug 25.PMID: 27569526 

 

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; EUFEST study group.Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95. doi: 10.1017/S1461145712001241. Epub 2012 Dec 20.PMID: 23253821 

 

Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?

Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS; EUFEST Study Group.J Clin Psychopharmacol. 2010 Apr;30(2):176-80. doi: 10.1097/JCP.0b013e3181d2193c.PMID: 20520291